← Markets

Vertex Pharmaceuticals Incorporated

VRTX · NASDAQ

Market closed$485.65$-0.380000 (-0.08%)After hours $485.88 · +0.05%

Key statistics

Previous close$486.03
Open$484.32
Day high$496.69
Day low$481.98
52-week high$533.67
52-week low$362.50
Market cap123.26B
Volume1.50M
Average volume1.49M
P/E ratio25.80
Forward P/E—
EPS18.82
Dividend yield0.00%

Market context

Why it moved

VRTX edged slightly lower despite broadly positive sentiment, as profit-taking and a few analyst price target trims weighed on the stock after its recent run near record highs, even as the company's strong cystic fibrosis franchise momentum and the FDA's acceptance of its BLA for povetacicept in nephrology continue to underpin long-term bullish consensus.

MarketbeatMarketbeatTheglobeandmailMarketbeatFacebook

What is happening

Recent company-specific developments and publisher coverage.

July 17, 2026Vertex Pharmaceuticals closed essentially flat amid a broader tech-driven market pullback, with the healthcare sector seeing mixed performance. Investor focus remains on Vertex's strong execution narrative: the company reiterated full-year 2026 revenue guidance of $12.95B–$13.1B following a Q1 beat, driven by ALYFTREK's CF launch momentum, growing CASGEVY infusions, and accelerating JOURNAVX prescriptions in pain. A newly disclosed $1.2M Q2 lobbying spend and a median analyst price target of $572 from 17 analysts underscore continued institutional interest, even as geopolitical tensions and AI-sector rotation weighed on broader markets.

-0.0782

July 17, 2026Vertex Pharmaceuticals closed nearly 2% higher, outperforming the broader healthcare sector (XLV closed modestly lower) as investors responded to a confluence of positive catalysts. UBS raised its price target on VRTX to $585 while maintaining a Buy rating, and the stock's upcoming Q2 earnings report (expected August 3) is drawing attention given the company's consistent history of beating EPS estimates — analysts project $4.25/share, up ~6% year-over-year. The broader healthcare sector also received a lift from UnitedHealth Group's strong Q2 earnings beat and raised guidance, while UBS highlighted biotechnology as a key allocation focus amid improving earnings revisions and M&A tailwinds.

1.876

July 15, 2026Vertex Pharmaceuticals edged lower as investors continue to digest two major developments: the FDA's expanded approval of gene therapy CASGEVY to children as young as 2 with sickle cell disease or beta thalassemia, and its $10 billion acquisition of Crinetics Pharmaceuticals announced July 11. While the CASGEVY label expansion broadens the addressable market, the Crinetics deal—financed partly with $4.5B in bridge debt—has weighed on sentiment, with shares down ~9% over the past week. Analysts remain broadly bullish, with UBS raising its price target to $585 and Truist lifting to $560, and Q2 earnings due August 3 expected to show continued EPS growth.

-0.8204

July 14, 2026Vertex Pharmaceuticals closed modestly lower amid a broader market selloff driven by renewed U.S.-Iran tensions and surging oil prices, though investor focus remains squarely on the company's $10 billion acquisition of Crinetics Pharmaceuticals—a deal that initially wiped roughly $10.9 billion in market value last week. Multiple analysts reaffirmed bullish outlooks on the strategic move, with BofA raising its price target to $600, UBS lifting to $585, and Truist boosting to $560, all maintaining Buy ratings. Additional catalysts include the expanded FDA approval of CASGEVY for children as young as 2 with sickle cell disease and a Canadian LOI for ALYFTREK, broadening Vertex's commercial reach ahead of its Q2 earnings report due August 3.

-1.0589

July 11, 2026Vertex Pharmaceuticals fell over 2% as investors continued to weigh the company's $10 billion acquisition of Crinetics Pharmaceuticals, announced July 7, which sent shares lower on deal-cost concerns despite the strategic rationale. The deal, priced at $85/share — a ~102% premium — adds Crinetics' marketed acromegaly drug Palsonify and a Phase 3 pipeline asset that Vertex projects could generate over $5B in peak combined revenue, but the hefty price tag and bridge financing from Bank of America and Morgan Stanley have weighed on sentiment. Divergent analyst views add to uncertainty: Baird set a bearish $350 price target while RBC Capital maintained a bullish $570 target, both issued July 7.

-2.2377

July 10, 2026Vertex Pharmaceuticals closed modestly lower as investors continued to digest the company's $10 billion acquisition of Crinetics Pharmaceuticals, announced July 7, which sent VRTX down roughly 4.6% on Wednesday. The deal — priced at $85/share in cash for Crinetics — is expected to add Palsonify (an FDA-approved acromegaly drug) and a Phase 3 pipeline asset with combined peak revenue potential of $5B+, but the deal's scale and reliance on debt financing has weighed on shares. Analyst reactions were mixed, with RBC setting a $570 target and Baird cutting its target to $350, while broader macro headwinds from U.S.-Iran military escalation and inflation concerns added pressure across healthcare and equity markets.

-0.3872

July 9, 2026Vertex Pharmaceuticals fell sharply after announcing a $10 billion acquisition of Crinetics Pharmaceuticals, with shares declining roughly 4.6% on above-average volume as investors weighed the deal's cost against its strategic merits. The company agreed to pay $85 per share in cash — a ~102% premium — for Crinetics and its FDA-approved acromegaly drug Palsonify, with peak combined revenue potential cited at over $5 billion; the deal will be financed via $4.5 billion in bridge financing plus existing cash. Jefferies raised its price target to $610 from $580, and biotech M&A sentiment remains broadly constructive amid a broader market risk-off session triggered by U.S.-Iran ceasefire tensions and surging oil prices.

-4.561

July 8, 2026Vertex Pharmaceuticals closed modestly lower despite a broadly stronger healthcare sector, as investors weighed the company's landmark $10 billion all-cash acquisition of Crinetics Pharmaceuticals. The deal, announced Monday evening, adds Palsonify—an FDA-approved oral acromegaly therapy—and Phase 3 candidate atumelnant for congenital adrenal hyperplasia, with Vertex projecting over $5 billion in combined peak annual revenue from the two assets. While the acquisition signals an aggressive push to diversify beyond cystic fibrosis into endocrinology, typical acquirer pressure and deal financing concerns (including $4.5 billion in bridge financing) weighed on shares, even as analysts at RBC raised their price target to $570 and UBS maintained a Buy rating. The broader healthcare sector outperformed, with XLV near its 52-week high, and Jim Cramer called biotech "the hottest group in the market," citing Vertex as a franchise with confirmed data that commands premium dealmaking prices.

-1.386

Simply Wall Street · July 15, 2026Vertex (VRTX) Is Buying Crinetics For $10 Billion To Enter Adrenal DiseaseSTAT · July 6, 2026Vertex acquires Crinetics Pharmaceuticals for $10 billion as biotech M&A boomsBusiness Wire · July 6, 2026Vertex to Acquire Crinetics PharmaceuticalsStock Titan · February 12, 2026Non-opioid pain pill and gene therapy help fuel Vertex’s $12B year
Benzinga · July 15, 2026$1000 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much Today
Benzinga · July 13, 2026UBS Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $585
Benzinga · July 13, 2026Truist Securities Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $560
Benzinga · July 9, 2026Nvidia, Vertex Pharmaceuticals And More On CNBC’s ‘Final Trades’
Mt Newswire · July 8, 2026Jefferies Adjusts Vertex Pharmaceuticals Price Target to $610 From $580
Mt Newswire · July 7, 2026Top Midday Gainers
Mt Newswire · July 7, 2026Vertex Pharmaceuticals' Acquisition of Crinetics Adds Rare-Disease Drugs, UBS Says
Mt Newswire · July 7, 2026Sector Update: Healthcare Stocks Gain Tuesday Afternoon

Peers

S&P 500SPX · $7,457.78-1.01%Gilead Sciences, Inc.GILD · $134.28-1.48%Amgen Inc.AMGN · $366.29-1.42%Regeneron Pharmaceuticals, Inc.REGN · $676.69-0.33%AbbVie Inc.ABBV · $254.49+0.04%Alnylam Pharmaceuticals, Inc.ALNY · $267.47-5.54%Biogen Inc.BIIB · $205.99-1.40%Intellia Therapeutics, Inc.NTLA · $11.38-4.09%CRISPR Therapeutics AGCRSP · $47.78-1.63%argenx SEARGX · $860.55+0.30%Novartis AGNVS · $153.76+0.67%Eli Lilly and CompanyLLY · $1,179.09+0.85%